Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Medexus Pharmaceuticals Inc (MDP.TO)

Medexus Pharmaceuticals Inc (MDP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 89,804
  • Shares Outstanding, K 32,420
  • Annual Sales, $ 108,332 K
  • Annual Income, $ 2,247 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.71
  • Price/Sales 0.59
  • Price/Cash Flow 3.78
  • Price/Book 1.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year 0.04
  • Growth Rate Est. (year over year) -125.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.52 +9.92%
on 12/12/25
2.80 -1.07%
on 12/24/25
+0.06 (+2.21%)
since 11/24/25
3-Month
2.51 +10.36%
on 11/20/25
3.00 -7.67%
on 09/25/25
-0.22 (-7.36%)
since 09/24/25
52-Week
1.96 +41.33%
on 04/07/25
5.56 -50.18%
on 01/22/25
-0.48 (-14.77%)
since 12/24/24

Most Recent Stories

More News
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 20, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the Toronto Stock Exchange has accepted Medexus's...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today entered into a new senior secured credit agreement with National Bank...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP)...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Schedules Second Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 25, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection

Fiscal Q1 2026 net revenue of $24.6 million, net income of $0.5 million, operating income of $0.9 million, and Adjusted EBITDA* of $3.4 million$3.0 million of product-level net revenue from GRAFAPEX in...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Schedules First Fiscal Quarter 2026 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, August...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States

Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEXâ„¢ executed...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26,...

MEDXF : 2.0200 (+1.50%)
MDP.TO : 2.77 (-0.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases,...

See More

Key Turning Points

3rd Resistance Point 2.93
2nd Resistance Point 2.86
1st Resistance Point 2.82
Last Price 2.77
1st Support Level 2.71
2nd Support Level 2.64
3rd Support Level 2.60

See More

52-Week High 5.56
Fibonacci 61.8% 4.18
Fibonacci 50% 3.76
Fibonacci 38.2% 3.34
Last Price 2.77
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar